Intensity modulated radiotherapy for breast cancer
 
Status Discontinued
Process MTA
Referral date 01 March 2008
Topic area
  • Cancer
  • Therapeutic procedures

Provisional Schedule

Consultation on draft scope by stakeholders: August 2007
Information meeting with consultees: 02 September 2008
Closing date for invited submissions / evidence submission: 27 October 2008
Final scope published: July 2008
1st appraisal committee meeting: TBC
2nd appraisal committee meeting: TBC

Project Team

Assessment Group / Evidence Review Group: School of Health and Related Research, University of Sheffield
Communications manager: Sarita Tamber
Executive Lead: Gillian Leng
Project manager: Jeremy Powell
Technical Lead: Elangovan Gajraj

Consultees

Manufacturers / Sponsors Elekta Limited (various)
  Siemens Medical Solutions (various)
  TomoTherapy (Hi Art)
  Varian Medical Systems UK Ltd (various)
Others Department of Health
  Knowsley PCT
  Surrey PCT
  Welsh Assembly Government
Patient / Carer Groups Afiya Trust
  Age Concern England
  Black Health Agency (BHA)
  Breakthrough Breast Cancer
  Breast Cancer Campaign
  Breast Cancer Care
  Breast Cancer Haven
  British Ethnic Health Awareness Foundation (BEHAF)
  CANCERactive
  Cancerbackup
  Cancer Black Care
  Cancer Equality
  Cancer Voices
  Chinese National Healthy Living Centre
  Confederation of Indian Organisations
  Counsel and Care
  Equalities National Council
  Helen Rollason Heal Cancer Charity
  Help the Aged
  Macmillan Cancer Support
  Maggie's Centres
  Marie Curie Cancer Care
  Muslim Council of Great Britain
  Muslim Health Network
  National Cancer Alliance
  National Council for Palliative Care
  Specialised Healthcare Alliance
  South Asian Health Foundation
  Sue Ryder Care
  Tenovus Cancer Information Centre
  Women's Health Concern
Professional groups Association of Cancer Physicians
  Association of Surgeons of Great Britain and Ireland
  British Association for Services to the Elderly
  British Geriatrics Society
  British Oncological Association (BOA)
  British Psychosocial Oncology Society (BPOS)
  Cancer Research UK
  Institute of Physics and Engineering in Medicine (IPEM)
  Royal College of Anaesthetists
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians, Medical Oncology Joint Special Committee
  Royal College of Radiologists
  Royal College of Surgeons
  Royal Society of Medicine – Intellectual Disabilities Forum
  Society and College of Radiographers
  United KingdomOncology Nursing Society

Commentators

Assessment Group School of Health and Related Research Sheffield
  National Coordinating Centre for Health Technology Assessment
Associated Guideline Groups National Collaborating Centre for Cancer
Associated Public Health Groups None
Comparator manufacturer(s) Elekta Limited (3D CRT)
  Siemens Medical Solutions (3D CRT)
  Varian Medical Systems UK Ltd (3D CRT)
General Age Concern Cymru
  Association of British Healthcare Industries (ABHI)
  Board of Community Health Councils in Wales
  British National Formulary
  Cancer Care Cymru
  Department of Health,Social Services and Public Safety for Northern Ireland
  EUCOMED
  Medicines and Healthcare products Regulatory Agency
  National Association for Primary Care
  National Public Health Service for Wales
  NHS Alliance
  NHS Confederation
  NHS Purchasing and Supply Agency
  NHS Quality Improvement Scotland
  Scottish Medicines Consortium
Relevant research groups Against Breast Cancer
  Breast Cancer Hope
  Breast Cancer Research Trust
  Cochrane Collaboration – Cochrane Breast Cancer Group
  Instituteof Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  Policy Research Institute on Ageing and Ethnicity
  Pro Cancer Research Fund
  Radiological Research Trust
  Research Institute for the Care of Older People

Timeline

Key events during the development of the guidance:

Date Update
24 June 2008 The appraisal was removed from the NICE work programme.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance